RFA-DA-26-020-Full-Announcement.html

The document is a Request for Application (RFA) from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, seeking applications to establish a dynamic drug development infrastructure focused on substance use disorders (SUDs). The initiative aims to create a center that provides comprehensive services to academic and biotech researchers, including Target Product Profiles creation, Freedom-to-Operate analysis, intellectual property consultations, regulatory guidance, and technical pipeline support for repurposing and repositioning medications for SUD treatment.

The grant opportunity is classified under the Drug Use and Addiction Research Programs (CFDA 93.279) and will be awarded as a Cooperative Agreement (U54 activity code). While specific funding amounts are not detailed, the program typically supports projects ranging from $41,000 to $7.3 million with project periods of 1-5 years. The center will be responsible for engaging the research community, soliciting proposals, and implementing processes to evaluate and advance high-quality projects addressing different SUD indications. Ideal applicants will have expertise in pharmacology, toxicology, neuroscience, in silico discovery, target validation, preclinical development, clinical protocol development, regulatory affairs, and intellectual property management.